Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Trial Profile

Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Dasatinib (Primary) ; Temozolomide
  • Indications Astrocytoma; Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 02 Jun 2015 The phase I results established the MTD and phase II dose of dasatinib to be 150 mg PO daily when given with temozolomide and radiotherapy, according to the abstract presented at ASCO 2015.
    • 02 Jun 2015 Interim results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top